Author/Authors
Çetin, Durmuş Ali Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi - Gastroenteroloji Cerrahisi Kliniği, Turkey , Gündeş, Ebubekir Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi - Gastroenteroloji Cerrahisi Kliniği, Turkey , Aday, Ulaş Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi - Gastroenteroloji Cerrahisi Kliniği, Turkey , Çiyiltepe, Hüseyin Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi - Gastroenteroloji Cerrahisi Kliniği, Turkey , Değer, Kamuran Cumhur Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi - Gastroenteroloji Cerrahisi Kliniği, Turkey , Duman, Mustafa Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi - Gastroenteroloji Cerrahisi Kliniği, Turkey
Title Of Article
Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case
شماره ركورد
27306
Abstract
Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few intestinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal perforation after bevacizumab treatment ten months after a metastatic colon cancer surgery.
From Page
168
NaturalLanguageKeyword
Bevacizumab , intestinal perforation , metastatic colorectal cancer
JournalTitle
Dicle Medical Journal
To Page
170
JournalTitle
Dicle Medical Journal
Link To Document